Free Trial

BridgeBio Pharma (BBIO) Insider Trading & Ownership

BridgeBio Pharma logo
$26.49 +0.28 (+1.07%)
(As of 12/20/2024 05:31 PM ET)

BridgeBio Pharma (NASDAQ:BBIO) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
24.66%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
6
Amount Of
Insider Selling
(Last 12 Months)
$155.27 M
Get BBIO Insider Trade Alerts

Want to know when executives and insiders are buying or selling BridgeBio Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

BBIO Insider Buying and Selling by Quarter

BridgeBio Pharma Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/19/2024Brian C StephensonCFOSell4,156$22.41$93,135.96  
11/19/2024Neil KumarCEOSell27,389$22.41$613,787.49  
9/13/2024Genetic Disorder L.P. KkrMajor ShareholderSell5,800,000$25.75$149,350,000.00  
8/19/2024Brian C StephensonCFOSell4,155$24.69$102,586.95  
8/19/2024Neil KumarCEOSell27,389$24.69$676,234.41  
6/3/2024Randal W ScottDirectorSell1,000$28.84$28,840.00  
3/1/2024Randal W ScottDirectorSell2,500$34.00$85,000.00  
1/16/2024Hannah ValantineDirectorSell2,915$37.97$110,682.55  
12/26/2023Frank MccormickDirectorSell100,000$42.06$4,206,000.00  
(Data available from 1/1/2013 forward)

BBIO Insider Trading Activity - Frequently Asked Questions

The list of insiders at BridgeBio Pharma includes Brian C Stephenson, Douglas A Dachille, Frank Mccormick, Genetic Disorder L.P. Kkr, Global Investors Lp Viking, Hannah Valantine, Neil Kumar, Randal W Scott, and Ronald J Daniels. Learn more on insiders at BBIO.

24.66% of BridgeBio Pharma stock is owned by insiders. Learn more on BBIO's insider holdings.

The following insiders have sold BBIO shares in the last 24 months: Brian C Stephenson ($4,096,222.54), Frank Mccormick ($4,206,000.00), Genetic Disorder L.P. Kkr ($149,350,000.00), Global Investors Lp Viking ($52,500,000.00), Hannah Valantine ($110,682.55), Neil Kumar ($9,467,071.70), and Randal W Scott ($193,840.00).

Insiders have sold a total of 8,404,502 BridgeBio Pharma shares in the last 24 months for a total of $219,923,816.79 sold.

BridgeBio Pharma Key Executives

  • Dr. Neil Kumar Ph.D. (Age 45)
    Co-Founder, President, CEO & Director
    Compensation: $1.53M
  • Dr. Charles J. Homcy M.D. (Age 76)
    Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
    Compensation: $563.2k
  • Dr. Frank P. McCormick Ph.D. (Age 74)
    Co-Founder, Chairman of Oncology & Director
    Compensation: $542.78k
  • Dr. Brian C. Stephenson C.F.A. (Age 43)
    Ph.D., CFO & Secretary
    Compensation: $1.15M
  • Dr. Richard H. Scheller Ph.D. (Age 71)
    Chairman of Research & Development
    Compensation: $509.62k
  • Dr. Uma Sinha Ph.D. (Age 66)
    Chief Scientific Officer
    Compensation: $1.31M
  • Grace Rauh
    Vice President of Communications
  • Mr. Eli M. Wallace Ph.D. (Age 57)
    Chief Scientific Officer of Oncology
  • Dr. Thomas Trimarchi Ph.D.
    Chief Product Officer
  • Dr. Eric Michael David J.D. (Age 52)
    M.D., Ph.D., Chief Executive Officer of Gene Therapy


This page (NASDAQ:BBIO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners